Icotrokinra (acetate)
Icotrokinra (JNJ-77242113) acetate is an orally available, selective antagonist of the IL-23 receptor. Icotrokinra acetate inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells (IC50=5.6 pM) and inhibits IL-23-induced interferon IFN-γ production in NK cells with an IC50 of 18.4 pM. Icotrokinra acetate exhibits anti-inflammatory activity in a rat TNBS-induced colitis model. Icotrokinra acetate can be used in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease[1].
Product Specifications
Product Name Alternative
JNJ-77242113 (acetate) ; JNJ-2113 (acetate) ; PN-235 (acetate)
UNSPSC
12352209
Target
IFNAR; Interleukin Related; STAT
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Field of Research
Inflammation/Immunology
Purity
99.65
Smiles
Molecular Formula
C90H120N20O22S2·xC2H4O2
Molecular Weight
1898.17 (free base)
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported
Isoform
IL-23
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog